{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-097001","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.158510+00:00","generated_at":"2026-05-31T09:14:53.982241+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M","bullets":["ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.","CNSide diagnostic met primary endpoint: helped clinical decisions in >90% of cases; tumor cell detection 80% vs 29% cytology.","Received $3.3M CPRIT grant in June 2024 for Rhenium (186Re) Obisbemeda development.","Cash $8.4M at June 30; H1 net loss $6.2M ($1.15/share) vs $6.3M ($2.60/share) year ago.","Upcoming: complete ReSPECT-LM Phase 1 single-dose, initiate multiple-dose Phase 1, and IND for pediatric trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-097001","json":"https://secwatch.observer/filing/0000950170-24-097001.json","markdown":"https://secwatch.observer/filing/0000950170-24-097001.md","text":"https://secwatch.observer/filing/0000950170-24-097001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/0000950170-24-097001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024097001/pstv-20240814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:14:53.982241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}